Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura

Scully, Marie; R. Cataland, Spero; Peyvandi, Flora; Coppo, Paul; Knöbl, Paul; A. Kremer Hovinga, Johanna; Metjian, Ara; de la Rubia, Javier; Pavenski, Katerina; Callewaert, Filip; Biswas, Debjit; De Winter, Hilde; K. Zeldin, Robert

doi:10.1056/nejmoa1806311

Public

Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura

Published in New England Journal of Medicine • Jan 9, 2019

Authors:

Marie Scully

Spero R. Cataland

Flora Peyvandi

Abstract

BACKGROUND: In acquired thrombotic thrombocytopenic purpura (TTP), an immune-mediated deficiency of the von Willebrand factor-cleaving protease ADAMTS13 allows unrestrained adhesion of von Willebrand factor multimers to platelets and microthrombosis, which result in thrombocytopenia, hemolytic anemi...

Subject

Medicine

Von Willebrand factor

ADAMTS13

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!